Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy

Table 2 Mean viral kinetic parameters of each HCV genotype and treatment schedule group in non-cirrhotic patients

	IFN doseand schedule	n	1st phase decline1(log IU/mL)	2nd phaseslope2 (log/wk)
HCV genotype 1	3 TIW	5		0.09
	3 Q2D	4		0.12
	3 QD	7		0.15
	9 QD	5		0.27
Total non-cirrhotic		21	1.03	0.18
HCV genotype 3	3 TIW	3		0.9
	3 Q2D	3		0.78
	3 QD	2		0.96
	9 QD	5		1.11b
Total non-cirrhotic		13	1.65b	0.99b

¹Treatment during the 1^st phase decline was equal in all dosing groups and thus was not given separately.

²There was no significant difference in the 2^nd phase decline slope between dosing groups per genotype.

^bP < 0.001 vs genotype 1.